肾康注射液与疏血通注射液治疗慢性肾脏病临床疗效比较

Comparison of Clinical Efficacy of Shenkang Injection and Shuxuetong Injection on Chronic Kidney Disease

目的:比较两种中药注射剂(肾康注射液与疏血通注射液)治疗慢性肾脏病的疗效。方法:回顾性分析157例接受保守治疗的慢性肾脏病患者的临床资料,根据不同中药注射剂治疗的选择,分为A组(肾康组)和B组(疏血通组),比较两组患者的肾功能变化及血红蛋白的差异,并进行统计学分析。结果:共有157例患者纳入研究,A组83例,B组74例。A组治疗后血红蛋白较治疗前下降(P<0.05),但两组间比较总的下降值及各分期下降值比较,差异均无统计学意义(P>0.05);尿素氮及肌酐下降,A组明显优于B组(P<0.05),二次分析发现,排除Aon C(慢性肾脏病急性加重)及糖尿病后比较,A组血肌酐及GFR较治疗前均有明显改善(P=0.043和P=0.048),B组血肌酐及GFR较治疗前无明显改善(P=0.46和P=0.299)。结论:肾康注射液对慢性肾脏病肾功能改善优于疏血通注射液,有降低血红蛋白的趋势。对合并糖尿病的慢性肾脏病患者,疏血通注射液可能有一定优势。

Objective： To compare the clinical efficacy of two kinds of traditional Chinese medicine injections （Shenkang in- jection and shuxuetong injection） on chronic kidney disease. Method： According to the different treatment of traditional Chinese medicine injections, the 157 patients with chronic kidney disease were divided into group A （Shenkang injection Group, 83 cas- es） and group B （shuxuetong injection Group, 74 cases） hemoglobin was observed. Results： The hemoglobin decreased for statistical analysis. After treatment, the renal function and after treatment than before treatment in group A（P〈0.05）, but the reduction in two groups showed no statistical significance （P〉0.05）. The decrease of urea nitrogen and creatinine of group A was bigger than group B （P〈0.05）. Further analysis explored that group A obviously improved in Cr and GFR （P=0.043 and P=0.048） after excluded AonC （chronic kidney disease acute aggravated） and the diabetes, but the outcome cannot be seen in group B （P=0.46 and P=0.299）. Conclusion： Shenkang injection shows better effects on renal function than shuxuetong injection in treat chronic kidney disease, and has the tendency of reducing hemoglobin. For patients with chronic kidney disease combined dia- betes, shuxuetong injection may have certain advantages.